How much profit has Crossject made this year?
Crossject has made 1.82 M EUR this year.
Crossject Net Income 2024
Crossject Net Income
1.82 M EUR
Crossject Dividend yield
Ticker
ALCJ.PA
ISIN
FR0011716265
WKN
A1XEH4
In 2024, Crossject's profit amounted to 1.82 M EUR, a -113.75% increase from the -13.21 M EUR profit recorded in the previous year.
The Crossject Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023e | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
Crossject Aktienanalyse
What does Crossject do?
Crossject SA is a company that specializes in the development and manufacturing of innovative drug delivery systems. The company was founded in 2006 by a team of professionals with the goal of changing the way medications are administered. Crossject's history began with the development of a unique drug delivery system called ZENEO. This system is based on a proprietary technology called "Needle Free Injection" that allows for needle-free and painless medication administration. The technology is safe, easy to use, and enables the administration of liquid medications and even solids in the form of suspensions. Crossject specializes in the application of this technology and develops products in various areas, including adrenaline for the treatment of life-threatening allergic reactions, methotrexate for the treatment of cancer, and anti-inflammatory medications for the treatment of asthma and COPD. The business model of Crossject is based on the development and commercialization of products based on the ZENEO technology. The company collaborates with a range of partners to bring its products to market, including pharmaceutical companies and other drug manufacturers. Crossject aims to sell its products worldwide and already has distribution partners in various countries around the world. Crossject is also committed to advancing the development of new products based on this technology. The company invests a significant portion of its revenue in research and development and works closely with academic institutions and other research facilities to improve its technology and products. Crossject's product offering includes a wide range of medications used for the treatment of various conditions. One example is the adrenaline injection system developed for the rapid and effective treatment of anaphylactic shocks that can occur as severe allergic reactions in people with food allergies, insect venom allergies, or drug allergies. The system does not require a needle and is therefore easy and safe to handle. Another example is the methotrexate injection for the treatment of cancer and autoimmune diseases such as rheumatoid arthritis and psoriasis. Crossject has also developed a range of products to combat asthma and chronic obstructive pulmonary disease (COPD). In 2019, the company received regulatory approval for its first commercial ZENEO product as an emergency treatment for migraines. This product is a fast-acting migraine therapy that is administered subcutaneously to quickly and effectively relieve pain and accompanying symptoms of migraines. In summary, Crossject is an innovative company specializing in the development and commercialization of drug delivery systems. The company utilizes a proprietary technology that allows for needle-free and painless medication administration and collaborates closely with partners to sell its products worldwide. Crossject continues to invest in research and development to bring new products based on its technology to market and establish itself as a leading company in its field. Crossject ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Crossject's Profit Margins
The profit margins of Crossject represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Crossject's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Crossject's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Crossject's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Crossject’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Crossject Stock
How has the profit developed compared to last year?
The profit has increased by -113.75% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Crossject publish its earnings?
Crossject publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Crossject?
The profits of Crossject are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Crossject?
You can learn more about the earnings of Crossject by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Crossject pay?
Over the past 12 months, Crossject paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Crossject is expected to pay a dividend of 0 EUR.
What is the dividend yield of Crossject?
The current dividend yield of Crossject is .
When does Crossject pay dividends?
Crossject pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Crossject?
Crossject paid dividends every year for the past 0 years.
What is the dividend of Crossject?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Crossject located?
Crossject is assigned to the 'Health' sector.
Wann musste ich die Aktien von Crossject kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Crossject from 5/2/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/2/2024.
When did Crossject pay the last dividend?
The last dividend was paid out on 5/2/2024.
What was the dividend of Crossject in the year 2023?
In the year 2023, Crossject distributed 0 EUR as dividends.
In which currency does Crossject pay out the dividend?
The dividends of Crossject are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Crossject
Our stock analysis for Crossject Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Crossject Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
